PT 141 Amino Asylum is a research-grade bremelanotide peptide sold for lab use only. Learn routes, reported duration, safety warnings, and how to vet vendors.
PT-141 from Amino Asylum is a research-grade vial of bremelanotide, a melanocortin receptor agonist that the FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Amino Asylum sells it as a laboratory chemical labeled 'not for human consumption,' so the vial is not a prescription medicine and is not FDA-approved in that form. Anyone comparing vendors needs to understand what the peptide is, how the approved drug differs, and what the published data do and do not show.
What PT-141 (Bremelanotide) Is and How It Works
Bremelanotide is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. It binds melanocortin receptors, primarily MC4R with some activity at MC1R, which is the mechanism researchers link to its effects on sexual desire and on pigmentation. It was first studied as a self-tanning agent before trials turned up changes in arousal.
- Peptide class: melanocortin receptor agonist
- FDA-approved product: Vyleesi (bremelanotide), a 1.75 mg subcutaneous auto-injector
- Approved indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women
- Research chemical format: typically lyophilized powder in 10 mg vials
- Half-life: approximately 2.7 hours
PT-141 is not approved for men, and it is not approved for general recreational use. Only the branded auto-injector holds an FDA approval, and that approval is narrow.
Why People Search for Amino Asylum PT 141
Amino Asylum is a US-based supplier of peptides and research chemicals, and amino asylum pt 141 appears in searches because the company lists bremelanotide alongside compounds such as BPC-157 and TB-500. Most buyers are trying to confirm three things: that the vial holds what the label claims, that the batch has documentation, and that the price matches comparable suppliers.
A vendor listing is marketing, not evidence. A batch-specific certificate of analysis from an independent lab is the closest thing to verification this market offers, and a generic PDF that covers no lot number is worth very little.
Routes of Administration Studied in the Literature
Subcutaneous injection
Vyleesi is given as a 1.75 mg subcutaneous injection into the abdomen or thigh. The label limits use to one dose in 24 hours and no more than eight doses per month, and the clinical trials behind approval used this route.
Intranasal bremelanotide
Early clinical work used a pt-141 nasal spray, and those studies reported lower and more variable absorption than injection. That variability is one reason the approved product became a subcutaneous auto-injector instead of a nasal device.
| Route | Amount used in studies | Onset | Notes |
|---|---|---|---|
| Subcutaneous injection | 1.75 mg (approved dose) | About 30-60 minutes | Route used in the approval trials |
| Intranasal spray | 7.5-10 mg in early trials | About 30-60 minutes | Lower, more variable bioavailability |
| Oral | Not used | Not applicable | Peptides are degraded in the digestive tract |
How Long Does PT-141 Last?
A frequent search question is how long does pt-141 last, and the pharmacokinetic data give a clear starting point. Bremelanotide peaks in plasma roughly one hour after a subcutaneous dose and has a half-life of about 2.7 hours, so most of the drug clears within a day.
In trial data and user reports, effects on desire tend to be noticed within 30 to 60 minutes and can persist for several hours. Some people describe residual effects into the next day, which is part of why labeling permits only one dose per 24 hours.
Dosing Questions and Off-Label Use
Published dosing data center on premenopausal women, because that is the population Vyleesi was approved for. A pt-141 dosage used in the approval trials was 1.75 mg subcutaneously, while dose-finding work also examined 0.75 mg and 1.25 mg.
Data in men are far thinner. Early erectile dysfunction trials were discontinued, and much of what circulates online about pt-141 for men comes from anecdotal reports rather than controlled studies. Off-label assumptions should be treated as unproven.
Safety, Side Effects, and Legal Status
Bremelanotide is linked to transient increases in blood pressure, and Vyleesi carries a boxed warning about that effect. People with uncontrolled hypertension or known cardiovascular disease should not use it, and anyone managing a health condition or taking medication should speak with a healthcare professional first.
Reported side effects in trials include nausea, flushing, headache, and injection-site reactions. Nausea was the most common reason participants stopped treatment.
PT-141 is a prescription-only drug in the United States, and research chemical versions have not been evaluated by the FDA for human use. A product labeled 'not for human consumption' is not a legal substitute for a prescribed medicine.
Sourcing, Storage, and Handling
Anyone asking where to buy pt-141 is shopping in a market with very little regulatory oversight. Research peptides usually ship as lyophilized powder, are reconstituted with bacteriostatic water, and are then stored cold and protected from light.
- Look for a certificate of analysis tied to the specific lot number
- Confirm cold-chain shipping during warm months
- Keep powder refrigerated or frozen and reconstituted vials cold
- Avoid repeated freeze-thaw cycles, which degrade peptides
Good handling practices protect the sample; they do not make an unapproved product safe for human use.
Frequently Asked Questions
Is PT-141 from Amino Asylum safe for human use?
No. Amino Asylum sells bremelanotide as a research chemical labeled 'not for human consumption,' and the FDA has not evaluated it in that form. Even the approved prescription product carries a boxed warning about blood pressure increases. Anyone curious about bremelanotide should discuss the prescription version with a healthcare professional.
How long does PT-141 take to work and how long do the effects last?
Bremelanotide reaches peak plasma levels about one hour after a subcutaneous dose and has a half-life of roughly 2.7 hours, so most of the drug clears within a day. Reported effects typically begin within 30 to 60 minutes and can last several hours. Labeling limits use to one dose every 24 hours.
What is the difference between PT-141 and Vyleesi?
Vyleesi is the FDA-approved brand of bremelanotide, supplied as a 1.75 mg auto-injector for premenopausal women with hypoactive sexual desire disorder. Research chemical PT-141 contains the same active peptide but is sold as laboratory material with no approved human use, no dosing guarantee, and no pharmacy oversight.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.